Corticosteroids & Immunosuppression — Corticosteroids and immunosuppression risks - Pharmacology

SECTION 1

Historical Context & Motivation

The story of corticosteroids begins in the adrenal cortex, where endogenous hormones such as cortisol regulate metabolism, cardiovascular tone, and immune responses. Clinicians recognized early on that patients with adrenal insufficiency exhibited dramatic inflammatory pathology, hinting at the anti-inflammatory potential of adrenal extracts. The pharmaceutical development of synthetic corticosteroids over the twentieth century opened transformative therapeutic avenues—but simultaneously introduced a spectrum of immunosuppression-related risks that remain a central concern in modern pharmacotherapy. Understanding this historical trajectory is essential for appreciating why corticosteroid stewardship is among the most consequential skills in clinical medicine.

1929 • Isolation of Adrenal Cortex Extracts

Philip Hench and Edward Kendall at the Mayo Clinic began isolating compounds from the adrenal cortex, eventually identifying Compound E (cortisone) as a key bioactive molecule.

1948 • First Clinical Use in Rheumatoid Arthritis

Hench administered cortisone to a patient with severe rheumatoid arthritis, producing dramatic remission. This landmark event earned the 1950 Nobel Prize in Physiology or Medicine and ushered in the era of steroid therapy.

1955–1960 • Synthetic Corticosteroid Development

Prednisone, prednisolone, dexamethasone, and other synthetic analogs were developed with improved anti-inflammatory potency and reduced mineralocorticoid effects, enabling more targeted immunosuppressive regimens.

1970s–1980s • Recognition of Opportunistic Infection Risk

Large-scale clinical experience revealed that chronic corticosteroid use predisposed patients to opportunistic infections such as Pneumocystis jirovecii pneumonia, oral candidiasis, and reactivation tuberculosis, catalyzing risk-mitigation guidelines.

2000s–Present • Steroid-Sparing Strategies & Precision Dosing

Modern protocols emphasize steroid-sparing regimens using biologic agents, calcineurin inhibitors, and antimetabolites to minimize cumulative corticosteroid exposure and its attendant immunosuppression risks.

The central question that has driven pharmacology research for over seven decades is deceptively straightforward: how can clinicians harness the potent anti-inflammatory and immunosuppressive properties of corticosteroids while minimizing the risk of life-threatening infections, metabolic derangements, and immune dysfunction? Answering this question requires a firm grasp of corticosteroid molecular pharmacology, the dose-response relationship governing immune suppression, and the clinical frameworks for monitoring and mitigating adverse outcomes.

SECTION 2

Core Principles of Corticosteroid-Mediated Immunosuppression

Corticosteroids exert their immunosuppressive effects through a series of interconnected molecular and cellular mechanisms. At the heart of these processes is the intracellular glucocorticoid receptor (GR), a ligand-activated transcription factor belonging to the nuclear receptor superfamily. Upon corticosteroid binding, the GR-ligand complex translocates to the nucleus and modulates gene expression through both transactivation (upregulation of anti-inflammatory genes) and transrepression (suppression of pro-inflammatory gene transcription via inhibition of NF-κB and AP-1). These genomic effects account for the majority of the immunosuppressive activity observed clinically, although rapid non-genomic effects on cell membranes and intracellular signaling cascades also contribute, particularly at high doses.

Inhibition of Pro-inflammatory Cytokines

Corticosteroids suppress transcription of IL-1, IL-2, IL-6, TNF-α, and IFN-γ by inhibiting NF-κB and AP-1 signaling, thereby broadly dampening innate and adaptive immune activation.

Impairment of Leukocyte Function

Corticosteroids reduce neutrophil chemotaxis and adherence, promote lymphocyte apoptosis (particularly T cells), and inhibit monocyte/macrophage antigen presentation, collectively weakening immune surveillance.

Redistribution of Immune Cells

Within hours of administration, corticosteroids cause lymphopenia and monocytopenia through sequestration of these cells in lymphoid tissue, while paradoxically increasing circulating neutrophil counts (demargination).

Suppression of Humoral Immunity

Prolonged corticosteroid exposure impairs B-cell proliferation and immunoglobulin production, reducing the effectiveness of antibody-mediated defense and vaccine responses.

Dose- and Duration-Dependent Risk

Immunosuppression severity correlates with cumulative dose, daily dose intensity, and treatment duration. Doses ≥20 mg/day prednisone equivalent for ≥2 weeks significantly increase opportunistic infection risk.

✦

KEY TAKEAWAY

Think of the immune system as a security team patrolling a building. Corticosteroids act like a directive from management ordering guards to stand down, leave their posts, and ignore alarms. At low doses, only a few guards are reassigned—minor gaps in coverage. At high doses or over prolonged periods, entire floors go unmonitored, allowing intruders (opportunistic pathogens) to enter undetected. The goal of clinical corticosteroid management is to quiet the alarm system enough to reduce harmful inflammation without leaving critical zones undefended.

SECTION 3

Mechanism of Corticosteroid Immunosuppression — Visual Overview

This diagram traces the corticosteroid signaling cascade from receptor binding in the cytoplasm through nuclear translocation and gene modulation, culminating in the downstream immunosuppressive effects—including reduced cytokine production, impaired T-cell function, compromised antigen-presenting cell activity, and the resultant increased vulnerability to opportunistic infections. The bottom panel highlights the clinical threshold above which immunosuppression becomes a significant management concern.

As depicted in the diagram, the immunosuppressive cascade begins the moment a corticosteroid molecule crosses the cell membrane and engages the cytoplasmic glucocorticoid receptor. The resulting receptor-ligand complex dissociates from heat-shock proteins and enters the nucleus, where it exerts dual effects. Transactivation promotes expression of anti-inflammatory mediators such as lipocortin-1 (annexin A1), which inhibits phospholipase A₂ and thereby reduces prostaglandin and leukotriene synthesis. Simultaneously, transrepression silences the NF-κB and AP-1 transcription factor pathways, dramatically reducing the production of pro-inflammatory cytokines. The net effect is a broad-spectrum dampening of both innate and adaptive immunity, which—while therapeutically valuable—leaves patients vulnerable to infections they would normally clear without difficulty.

SECTION 4

Pharmacokinetic and Pharmacodynamic Considerations

Understanding the dose-response relationship for corticosteroid immunosuppression requires integrating pharmacokinetic parameters—absorption, distribution, metabolism, and elimination—with the pharmacodynamic effects on immune cell populations. Although corticosteroid immunosuppression does not lend itself to a single predictive equation in the same way that antibiotic dosing follows minimum inhibitory concentration (MIC) models, several quantitative frameworks guide clinical decision-making.

PREDNISONE EQUIVALENT DOSE

Prednisone Equivalent (mg) = Dose of Agent (mg) × (Relative Potency Factor)

Relative potency factors: hydrocortisone = 0.25, prednisone/prednisolone = 1.0, methylprednisolone = 1.25, dexamethasone = 6.67, betamethasone = 6.67. This conversion enables standardized risk assessment across different corticosteroid formulations.

CUMULATIVE DOSE ESTIMATION

Cumulative Dose (mg) = Daily Dose (mg) × Duration (days)

Cumulative prednisone-equivalent doses exceeding 700 mg (e.g., 20 mg/day × 35 days) are associated with markedly increased risk of opportunistic infection. This threshold is a clinical rule of thumb widely used in infectious disease consultations.

IMMUNOSUPPRESSION RISK THRESHOLD

Significant Risk ≈ ≥20 mg/day prednisone equivalent × ≥14 days

This widely cited guideline from the CDC and IDSA defines the threshold at which patients should be considered functionally immunosuppressed for purposes of live vaccine contraindication and opportunistic infection prophylaxis decisions.

Corticosteroid	Relative Anti-inflammatory Potency	Equivalent Dose (mg)	Biological Half-life (h)
Hydrocortisone	1	20	8–12
Prednisone	4	5	12–36
Methylprednisolone	5	4	12–36
Dexamethasone	25–30	0.75	36–54
Betamethasone	25–30	0.75	36–54

Corticosteroid Potency and Equivalence Table

Several clinical implications emerge from these pharmacokinetic parameters. Agents with longer biological half-lives, such as dexamethasone, produce prolonged immunosuppressive effects even after discontinuation, because the genomic changes they induce persist beyond the drug's plasma clearance. This concept—the dissociation between plasma half-life and biological half-life—is critical for anticipating infection windows. A patient who received a 10-day course of high-dose dexamethasone may remain immunosuppressed for days to weeks after the last dose, during which period vigilance for opportunistic infection must be maintained.

SECTION 5

Classification of Immunosuppression Risks

Opportunistic Infections by Pathogen Category

Corticosteroid-induced immunosuppression creates vulnerability across virtually all pathogen classes. The specific infections that emerge depend on the depth and duration of immune suppression, the patient's geographic and epidemiologic exposures, and the presence of co-administered immunosuppressive agents. Below we classify the major infection risks by pathogen type, highlighting those most commonly encountered in clinical practice and most relevant to pharmacology board examinations.

This risk-stratified diagram illustrates how infection susceptibility escalates with increasing cumulative corticosteroid exposure. The dashed curve represents the rising probability of serious opportunistic infection. The low-dose zone is associated mainly with mucocutaneous infections, the moderate zone with common bacterial and viral reactivation syndromes, and the high-dose zone with life-threatening invasive fungal, mycobacterial, and parasitic infections.

⚠

Clinical Pearl

Before initiating prolonged high-dose corticosteroid therapy, always screen for latent tuberculosis (via interferon-gamma release assay or tuberculin skin test), Strongyloides serology (especially in patients from endemic regions), and consider hepatitis B surface antigen testing. Corticosteroid-induced immunosuppression can cause fulminant reactivation of these latent infections with devastating consequences.

Pathogen Category	Key Organisms	Typical Presentation	Prophylaxis / Monitoring
Fungi	Pneumocystis jirovecii, Aspergillus, Candida, Cryptococcus	PJP: dyspnea, bilateral ground-glass opacities. Aspergillosis: pulmonary nodules, hemoptysis.	TMP-SMX prophylaxis for PJP when ≥20 mg pred equiv × ≥4 weeks. Galactomannan monitoring for aspergillosis.
Bacteria	Listeria, Nocardia, Mycobacterium tuberculosis	Meningitis (Listeria), pulmonary/disseminated disease (Tb, Nocardia).	IGRA or TST before therapy. Isoniazid for latent Tb.
Viruses	HSV, VZV, CMV, HBV	Herpes zoster, CMV viremia/colitis, HBV flare.	Antiviral prophylaxis if high risk. HBV screening and entecavir if HBsAg+.
Parasites	Strongyloides stercoralis, Toxoplasma gondii	Strongyloides hyperinfection syndrome: gram-negative sepsis, pulmonary infiltrates.	Serologic screening pre-therapy. Ivermectin treatment for positive serology.

Opportunistic Infections Associated with Corticosteroid Immunosuppression

SECTION 6

Worked Example — Assessing Immunosuppression Risk in a Clinical Scenario

Consider the following clinical scenario, which integrates pharmacokinetic concepts, dose equivalence calculations, and risk stratification principles.

Clinical Case: Post-Transplant Steroid Taper Assessment

1
Step 1 — Identify the Clinical Situation

A 58-year-old renal transplant recipient is receiving methylprednisolone 32 mg/day as part of a post-transplant immunosuppressive regimen. She has been on this dose for 21 days. You are asked to determine whether she meets criteria for significant immunosuppression and whether PJP prophylaxis is indicated.
2
Step 2 — Convert to Prednisone Equivalent

Methylprednisolone has a relative anti-inflammatory potency of 5 compared to hydrocortisone's 1, and its prednisone equivalence ratio is 1.25 (i.e., 4 mg methylprednisolone ≈ 5 mg prednisone). Therefore:

Prednisone equivalent = 32 mg × (5 mg prednisone / 4 mg methylprednisolone) = 40 mg/day prednisone equivalent
3
Step 3 — Assess Duration Against Threshold

The patient has been receiving 40 mg/day prednisone equivalent for 21 days. The CDC/IDSA threshold for significant immunosuppression is ≥20 mg/day for ≥14 days. This patient exceeds both the dose and duration criteria by a substantial margin.

Patient meets criteria for significant immunosuppression (40 mg/day × 21 days >> threshold of 20 mg/day × 14 days)
4
Step 4 — Calculate Cumulative Dose

Cumulative prednisone-equivalent dose = daily dose × duration.

Cumulative dose = 40 mg/day × 21 days = 840 mg cumulative prednisone equivalent — well above the 700 mg rule-of-thumb threshold for heightened opportunistic infection risk.
5
Step 5 — Clinical Decision

Given that this patient is significantly immunosuppressed by corticosteroid criteria alone—and also receiving other immunosuppressive agents (calcineurin inhibitor, mycophenolate) as part of her transplant regimen—the following actions are indicated:

Initiate TMP-SMX prophylaxis for PJP. Confirm that pre-transplant screening for latent Tb and Strongyloides was performed. Avoid live vaccines. Monitor for signs of CMV reactivation. Counsel patient regarding infection warning signs (fevers, cough, skin lesions).

SECTION 7

Balancing Therapeutic Benefits Against Immunosuppression Risks

The clinical utility of corticosteroids spans an enormous range of conditions—autoimmune diseases, organ transplant rejection, oncologic emergencies, and severe allergic reactions, among many others. The challenge lies in contextualizing the immunosuppressive risks against the often life-saving or function-preserving benefits. The following table presents a comparative framework for evaluating this balance across common clinical indications.

Clinical Indication	Typical Dose / Duration	Immunosuppression Risk Level	Key Mitigation Strategies
Acute asthma exacerbation	Prednisone 40–60 mg × 5–7 days	Low	Short course; generally no prophylaxis needed. Monitor for oral candidiasis if using inhaled corticosteroids concurrently.
Rheumatoid arthritis (bridging therapy)	Prednisone 10–20 mg/day × weeks to months	Moderate	Taper as DMARDs take effect. Screen for latent Tb. Consider PJP prophylaxis if other immunosuppressants used.
Organ transplant maintenance	Prednisone 5–10 mg/day long-term + other agents	High (cumulative)	PJP prophylaxis, CMV prophylaxis, annual influenza/pneumococcal vaccines, avoid live vaccines, Tb screening.
Oncologic (e.g., lymphoma, brain metastases)	Dexamethasone 4–16 mg/day × weeks	High	PJP prophylaxis mandatory. Monitor for invasive fungal infection. Screen Strongyloides in endemic populations. Taper ASAP.
Immune checkpoint inhibitor toxicity (irAEs)	Prednisone 1–2 mg/kg/day × 4–8 weeks	Very high	PJP prophylaxis, Tb screening, Strongyloides screening, aggressive taper schedule, consider infliximab for steroid-refractory cases to minimize steroid exposure.

Risk-Benefit Stratification by Clinical Indication

✦

KEY TAKEAWAY

Corticosteroid risk assessment is not binary—it exists on a continuum. A brief burst of prednisone for asthma carries minimal immunosuppressive risk, while the same drug at higher doses for weeks in an oncology patient demands a comprehensive prophylactic strategy. The clinician's role is analogous to a pilot adjusting thrust: enough power to reach altitude (therapeutic effect) without exceeding structural limits (immune compromise). Steroid-sparing agents serve as auxiliary engines that allow the corticosteroid 'throttle' to be pulled back while maintaining therapeutic momentum.

SECTION 8

Connection to Advanced Immunosuppressive Pharmacology

Corticosteroid-mediated immunosuppression represents the oldest and broadest pharmacologic approach to dampening immune responses, but modern immunology pharmacology has expanded the armamentarium considerably. Understanding corticosteroid immunosuppression in the context of more targeted agents illuminates both the unique risks of corticosteroids and the rationale for combination and steroid-sparing strategies. The table below compares corticosteroids with major classes of immunosuppressive agents along key pharmacologic dimensions.

Feature	Corticosteroids	Calcineurin Inhibitors (Tacrolimus, Cyclosporine)	Biologic Agents (Anti-TNF, Anti-IL-6)
Mechanism	Genomic: GR-mediated transactivation/transrepression; broad cytokine suppression	Inhibit calcineurin → block IL-2 transcription → selective T-cell suppression	Monoclonal antibodies targeting specific cytokines or receptors
Immune Suppression Breadth	Very broad (innate + adaptive)	Moderate (primarily T-cell mediated)	Narrow (single cytokine pathway)
Onset of Action	Hours (non-genomic) to days (genomic)	Days to weeks	Weeks to months
Infection Risk Profile	Opportunistic infections (fungal, mycobacterial, parasitic, viral)	BK virus nephropathy, CMV; moderate bacterial risk	Tb reactivation (anti-TNF), bacterial infections
Non-immune Adverse Effects	Hyperglycemia, osteoporosis, adrenal suppression, myopathy, psychosis	Nephrotoxicity, hypertension, neurotoxicity	Infusion reactions, autoantibody formation

Corticosteroids vs. Other Immunosuppressive Drug Classes

A critical concept in advanced immunosuppressive pharmacology is the notion of additive immunosuppressive risk. When corticosteroids are combined with other immunosuppressive agents—as is the norm in transplant medicine, oncology, and autoimmune disease management—the cumulative risk of infection exceeds that of any single agent alone. This principle has driven the development of steroid-sparing protocols in which targeted biologic agents assume the primary immunosuppressive role, allowing corticosteroid doses to be minimized or eliminated. The evolving landscape of selective glucocorticoid receptor modulators (SEGRMs) and dissociated glucocorticoid receptor agonists (DIGRAs) represents a frontier in pharmacology research aimed at preserving anti-inflammatory efficacy while attenuating the broad immunosuppressive and metabolic toxicities of traditional corticosteroids.

SECTION 9

Practice Problems

Question 1: CONCEPTUAL

Explain why corticosteroid-induced immunosuppression affects both innate and adaptive immunity, whereas calcineurin inhibitors primarily affect only adaptive immunity. Reference the molecular targets of each drug class in your answer.

Show answer

Corticosteroids act via the glucocorticoid receptor, which is expressed in virtually all immune cell types—neutrophils, macrophages, dendritic cells (innate), and T and B lymphocytes (adaptive). By inhibiting NF-κB and AP-1, corticosteroids suppress pro-inflammatory cytokine production across all these lineages, impair antigen presentation by dendritic cells and macrophages, and promote lymphocyte apoptosis. In contrast, calcineurin inhibitors (tacrolimus, cyclosporine) specifically block the calcineurin-NFAT signaling pathway in T cells, which is required for IL-2 transcription and T-cell activation. Since innate immune cells do not depend on calcineurin-NFAT signaling for their primary effector functions, calcineurin inhibitors largely spare innate immunity while selectively suppressing the T-cell arm of adaptive responses.

Question 2: BASIC CALCULATION

A patient is receiving dexamethasone 8 mg/day for 10 days as adjunctive therapy for brain metastases. Calculate the daily prednisone-equivalent dose and the cumulative prednisone-equivalent dose. Does this patient meet the threshold for significant immunosuppression?

Show answer

Dexamethasone has an anti-inflammatory potency approximately 25–30 times that of hydrocortisone. Using the equivalence ratio, 0.75 mg dexamethasone ≈ 5 mg prednisone. Therefore, 8 mg dexamethasone = 8 mg ÷ 0.75 mg × 5 mg = approximately 53.3 mg prednisone equivalent per day. The cumulative dose over 10 days = 53.3 mg/day × 10 days ≈ 533 mg. Since the daily dose (53.3 mg) far exceeds 20 mg/day and the duration (10 days) is below 14 days, the patient is borderline by the strict ≥20 mg × ≥14 days rule. However, given the very high daily dose and the fact that dexamethasone has a biological half-life of 36–54 hours, the immunosuppressive effect persists well beyond the 10-day course. Most clinicians would consider this patient functionally immunosuppressed and would initiate PJP prophylaxis.

Question 3: INTERMEDIATE

A 45-year-old woman with systemic lupus erythematosus is being transitioned from prednisone 30 mg/day to a steroid-sparing regimen with mycophenolate mofetil. Her rheumatologist plans to taper prednisone by 5 mg every 2 weeks. At what point during the taper would she fall below the CDC/IDSA threshold for significant immunosuppression (prednisone ≥20 mg/day × ≥14 days), and what factors complicate this assessment?

Show answer

Starting at 30 mg/day, the taper proceeds as follows: weeks 1–2 at 30 mg, weeks 3–4 at 25 mg, weeks 5–6 at 20 mg, weeks 7–8 at 15 mg. She falls below the 20 mg/day threshold at the start of week 7 (after 6 weeks at ≥20 mg/day). However, this simple calculation is complicated by several factors. First, she has accumulated a substantial cumulative dose—30 × 14 + 25 × 14 + 20 × 14 = 1,050 mg over the first 6 weeks—which means her immune system remains suppressed even at lower doses. Second, the addition of mycophenolate mofetil (an antimetabolite immunosuppressant) contributes additive immunosuppressive risk, so infection vigilance should not be relaxed simply because the prednisone dose drops below 20 mg. Third, corticosteroids cause adrenal suppression after prolonged use, and the HPA axis recovery lag may perpetuate immune dysfunction. PJP prophylaxis should typically be continued until both the corticosteroid dose is low and the patient is clinically stable on the steroid-sparing regimen.

Question 4: APPLIED

A 62-year-old man from Southeast Asia presents with eosinophilia and is about to start high-dose prednisone (60 mg/day) for autoimmune hepatitis. His infectious disease team is consulted. Outline the pre-treatment screening tests you would recommend and explain the rationale for each, with particular attention to a potentially life-threatening parasitic complication.

Show answer

The critical concern in this patient is Strongyloides stercoralis hyperinfection syndrome. Strongyloides is endemic in Southeast Asia, and this parasite has a unique autoinfection cycle that allows it to persist indefinitely in a host. Under normal immune surveillance, the parasite burden remains low. However, corticosteroid-induced immunosuppression can trigger hyperinfection, in which massive larval proliferation causes disseminated disease with gram-negative bacteremia (as larvae carry enteric bacteria through the bowel wall), respiratory failure, and multiorgan involvement with mortality rates exceeding 70%. Pre-treatment screening should include: (1) Strongyloides IgG serology—if positive, treat with ivermectin before initiating steroids; (2) interferon-gamma release assay (IGRA) or tuberculin skin test for latent tuberculosis—if positive, begin isoniazid prophylaxis; (3) hepatitis B surface antigen and core antibody—HBV reactivation under corticosteroids can cause fulminant hepatic failure; if HBsAg positive, initiate antiviral prophylaxis with entecavir; (4) baseline chest radiograph to evaluate for active pulmonary infection; (5) consider hepatitis C viral load given the autoimmune hepatitis context. Once steroids are initiated at this dose, TMP-SMX for PJP prophylaxis is also indicated.

Question 5: CRITICAL THINKING

Immune checkpoint inhibitors (ICIs) such as pembrolizumab enhance anti-tumor immunity by removing inhibitory signals on T cells. When patients develop severe immune-related adverse events (irAEs), high-dose corticosteroids are the first-line treatment. Discuss the pharmacologic paradox inherent in this approach: how does suppressing the immune system with corticosteroids interact with the anti-tumor mechanism of the checkpoint inhibitor? Consider the implications for both irAE management and oncologic outcomes.

Show answer

This scenario embodies one of the most challenging pharmacologic paradoxes in modern oncology. ICIs work by blocking PD-1/PD-L1 or CTLA-4, thereby unleashing T-cell mediated anti-tumor immunity. When this immune activation becomes misdirected against self-tissues (irAEs), high-dose corticosteroids are administered to suppress the very T-cell responses that the ICI was designed to amplify. The paradox has several dimensions. First, corticosteroids broadly suppress T-cell function, potentially attenuating the anti-tumor immune response and theoretically reducing the oncologic efficacy of the checkpoint inhibitor. Retrospective studies have yielded mixed results—some suggest that corticosteroid use for irAE management does not significantly worsen overall survival, possibly because irAE occurrence itself is a biomarker of robust anti-tumor immunity that persists even after partial pharmacologic suppression. Second, the corticosteroid-induced immunosuppression adds infection risk on top of the already altered immune landscape created by ICI therapy. Third, the dose and duration of corticosteroids for irAEs are often substantial (prednisone 1–2 mg/kg/day for weeks), placing patients squarely in the high-risk immunosuppression category. Current guidelines emphasize rapid taper schedules, use of steroid-sparing agents (e.g., infliximab for colitis, mycophenolate for hepatitis) to minimize cumulative corticosteroid exposure, and mandatory PJP prophylaxis. The ideal resolution to this paradox remains an active area of investigation, with researchers exploring selective immunosuppressive strategies that could dampen autoimmune tissue destruction without compromising anti-tumor immunity.

SUMMARY

Lesson Summary

Summary

Corticosteroids exert potent immunosuppressive effects through binding the intracellular glucocorticoid receptor (GR), leading to nuclear translocation and dual modulation of gene expression via transactivation of anti-inflammatory genes and transrepression of pro-inflammatory pathways (NF-κB, AP-1). These genomic actions suppress production of key cytokines (IL-1, IL-2, IL-6, TNF-α), impair T-cell and B-cell function, inhibit antigen-presenting cell activity, and redistribute lymphocytes to lymphoid tissue. The breadth of these effects—spanning both innate and adaptive immunity—distinguishes corticosteroids from more targeted immunosuppressive agents and accounts for the wide range of opportunistic infection risks associated with their use.

Immunosuppression severity is dose- and duration-dependent, with ≥20 mg/day prednisone equivalent for ≥14 days serving as the widely accepted threshold for significant immune compromise. Key infections of concern include Pneumocystis jirovecii pneumonia, reactivation tuberculosis, invasive aspergillosis, Strongyloides hyperinfection, and viral reactivation syndromes. Pre-treatment screening (Tb, Strongyloides, HBV), prophylactic antimicrobials (TMP-SMX for PJP), live vaccine avoidance, and steroid-sparing strategies are the pillars of safe corticosteroid prescribing. Mastery of dose equivalence calculations and risk stratification frameworks is essential for every healthcare professional who prescribes or manages patients receiving corticosteroid therapy.